跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
C5 inhibitor
首页
药物
C5 inhibitor
C5 inhibitor
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Methods and compositions for treating complement-associated disorders
EP 2894165 A1
申请人: ALEXION PHARMA INC
优先权: 2008
CN
EP
US
WO
21 件公开
Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US 7432356 B2
申请人: GENENTECH INC
优先权: 2002
US
9 件公开
Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
US 8258307 B2
申请人: SUGA HIROAKI
优先权: 2007
US
6 件公开
THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
EP 3661493 A4
申请人: ACHILLION PHARMACEUTICALS INC
优先权: 2017
CN
EP
US
WO
5 件公开
Use of complement inhibitors to treat ocular diseases
US 8753625 B2
申请人: FUNG SEK CHUNG
优先权: 2005
CN
US
5 件公开
SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
EP 4228758 C0
申请人: SANOFI SA
优先权: 2020
EP
US
WO
4 件公开
Methods for treating multiorgan, systemic degos' disease with a complement inhibitor
US 8999340 B2
申请人: MAGRO CYNTHIA
优先权: 2011
CN
US
4 件公开
METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING A COMPLEMENT ALTERNATIVE PATHWAY INHIBITOR
EP 4387728 A1
申请人: ALEXION PHARMA INC
优先权: 2021
EP
US
WO
3 件公开
TETRAHYDRONAPHTHALENE DERIVATIVE
EP 4501906 A1
申请人: ATRANSEN PHARMA LTD
优先权: 2022
EP
US
WO
3 件公开
ANTI-C5 ANTIBODY/C5 IRNA CO-FORMULATIONS AND COMBINATION THERAPIES
EP 4608449 A1
申请人: REGENERON PHARMA
优先权: 2022
EP
US
WO
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈